Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

March 13, 2023 0
Pfizer to Acquire Seagen Pfizer (PFE) is to acquire Seagen (SGEN) for $229 per share in cash, for a total enterprise value of approximately $43 billion Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, said, “Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public …

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001...

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy...

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002...

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant...

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene...

CytomX Therapeutics Provided an Important Strategic Update

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven...

Vertex Pharmaceuticals and Type 1 Diabetes

An Important Reminder from Vir Biotechnology

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s...

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little...

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s...

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office...

These Dangerous World Circumstances and the Prohost Portfolio

The FDA Authorized Emergency Use of Pfizer Paxlovid Pills Against...

The FDA Cleared the IND for Erasca Inc Product ERAS-801...

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9...

No Evidence of Data Manipulation in Technical Paper Foundational to...

Impacting News

What We Are Looking for in a Bear Market

March 11, 2023 0
The Stock Market The volatility continues in the Bear market with investors not knowing what to …

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

February 23, 2023 0
Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) is a biopharma firm developing novel products for debilitating and …

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

February 13, 2023 0
Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. …

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

February 2, 2023 0
CytomX Therapeutics  We posted several articles that brought good news from CytomX Therapeutics (CTMX), yet the …

TG Therapeutics Launched FDA Approved Product  BRIUMVI™ for Patients with Relapsing Forms of MS

January 27, 2023 0
TG Therapeutics  TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for …

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

January 20, 2023 0
Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals (JAZZ) and Zymeworks Inc. (ZYME)

Trick or Trade

Why the Current Interest in Ventyx Biosciences

March 7, 2023 0
The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus  We like the fact that Ventyx …

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

February 8, 2023 0
Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' …

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

February 7, 2023 0
Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel  treatments aimed at improving …

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

February 2, 2023 0
It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …
Stocks Outperforming Today

Stocks Outperforming Today

January 5, 2023 0
January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Promising Stocks in the First Two Trading Days of 2023

January 4, 2023 0
The Stock Market in the New Year It is still too early to tell how the …

Today’s Highlights

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

March 2, 2023 0
Intellia Therapeutics  Intellia Therapeutics (NTLA) announced that the U.S. FDA has cleared the company’s Investigational New …

Why Travere Therapeutics’ Stocks Did Not Fall During This Tuesday’s Bad Market

February 22, 2023 0
The Bear Market The volatility in the Bear stock market continues to plunge the values of …

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

February 3, 2023 0
Merck KEYTRUDA Announcement Merck (MRK) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination …

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

January 19, 2023 0
Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. (EDIT), announced that it has …

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 1
CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration …

Why Kala Pharmaceuticals Stock is Soaring

December 28, 2022 0
Kala Pharmaceuticals  Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug …

Prohost Letters

Gilead Sciences – Still Way Undervalued

December 29, 2022 0
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Treating Untreatable Disease – NASH

October 13, 2022 0
Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis  The efforts spent on treating …

Shorting Biotech Firms with Solid Fundamentals

July 19, 2022 0
Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems …

Bear Market. Bad Market. Unpredictable Market.

May 17, 2022 0
Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from …

Comprehensive Prohost Letter #449 – Reality

March 27, 2022 0
Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in …

Comprehensive Prohost Letter #448

December 22, 2021 0
Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron …

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2023.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement